Literature DB >> 13109107

An absolute method for assay of virus hemagglutinins.

S LEVINE, T T PUCK, B P SAGIK.   

Abstract

A rapid and precise method is described for determination of absolute numbers of hemagglutinating particles present in virus suspensions. The method involves spectrophotometric measurement of the number of red cells dimerized by the virus under conditions in which formation of larger aggregates is precluded. Results of this procedure are compared with those of titrations based on egg infectivity and the polystyrene microsphere electron micrography for influenza virus; and with plaque count titrations on chick embryo cell monolayers in the case of the virus of Newcastle disease. The agreement is well within the limits expected in view of the different quantities which the various procedures measure. The conversion factor for transforming titre in hemagglutinating units based on the pattern procedure into absolute number of agglutinating particles is the same for influenza and Newcastle disease virus. The precipitation of red blood cells by Newcastle disease virus at 23 degrees C. is optimal at pH's between 6.2 and 5.8.

Entities:  

Keywords:  HEMAGGLUTINATION; VIRUSES

Mesh:

Substances:

Year:  1953        PMID: 13109107      PMCID: PMC2136342          DOI: 10.1084/jem.98.6.521

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  4 in total

1.  Production of Plaques in Monolayer Tissue Cultures by Single Particles of an Animal Virus.

Authors:  R Dulbecco
Journal:  Proc Natl Acad Sci U S A       Date:  1952-08       Impact factor: 11.205

2.  Electron micrographic counts of bacteriophage particles.

Authors:  S E LURIA; R C WILLIAMS; R C BACKUS
Journal:  J Bacteriol       Date:  1951-02       Impact factor: 3.490

3.  Mutual exclusion between related phages.

Authors:  R DULBECCO
Journal:  J Bacteriol       Date:  1952-02       Impact factor: 3.490

4.  ADSORPTION OF INFLUENZA HEMAGGLUTININS AND VIRUS BY RED BLOOD CELLS.

Authors:  G K Hirst
Journal:  J Exp Med       Date:  1942-08-01       Impact factor: 14.307

  4 in total
  9 in total

1.  Viruses with segmented ribonucleic acid genomes: multiplication of influenza versus reovirus.

Authors:  A J Shatkin
Journal:  Bacteriol Rev       Date:  1971-09

2.  On the reproduction of influenza virus; quantitative studies with procedures which enumerate infective and hemagglutinating virus particles.

Authors:  F L HORSFALL
Journal:  J Exp Med       Date:  1954-08-01       Impact factor: 14.307

3.  Reproduction of influenza viruses; quantitative investigations with particle enumeration procedures on the dynamics of influenza A and B virus reproduction.

Authors:  F L HORSFALL
Journal:  J Exp Med       Date:  1955-10-01       Impact factor: 14.307

4.  Clonogenic assay of type a influenza viruses reveals noninfectious cell-killing (apoptosis-inducing) particles.

Authors:  John M Ngunjiri; Margaret J Sekellick; Philip I Marcus
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

5.  Problems of influenza virus vaccine standardization.

Authors:  N M Tauraso; T C O'Brien; E B Seligman
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

Review 6.  Virus-erythrocyte interactions.

Authors:  C Howe; L T Lee
Journal:  Adv Virus Res       Date:  1972       Impact factor: 9.937

7.  Quantitative aspects of the spontaneous elution of influenza virus from red cells.

Authors:  B SAGIK; T PUCK; S LEVINE
Journal:  J Exp Med       Date:  1954-03       Impact factor: 14.307

8.  Studies on host-virus interactions in the chick embryo-influenza virus system. XII. Further analyses of yields derived from heat-inactivated standard seeds.

Authors:  K PAUCKER; W HENLE
Journal:  J Exp Med       Date:  1955-05-01       Impact factor: 14.307

9.  Morphological and quantitative comparison between infectious and non-infectious forms of influenza virus.

Authors:  G H WERNER; R W SCHLESINGER
Journal:  J Exp Med       Date:  1954-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.